Skip to main content

Mallinckrodt Value Stock - Dividend - Research Selection

Mallinckrodt Pharmaceuticals

ISIN: IE00BBGT3753, WKN: A1W0TN

Market price date: 26.05.2020
Market price: 3,35 USD




Mallinckrodt Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2020
Cash flow
Net operating cash flow 742.900.000
Capital Expenditures -133.000.000
Free cash flow 609.900.032
Balance sheet
Total Equity 1.940.700.000
Liabilities & Shareholders equity 10.338.900.000
Income statement
Net income -996.500.000
Eps (diluted) -11,880
Diluted shares outstanding 83.880.500
Net sales/revenue 3.162.500.000

Fundamental ratios calculated on: 26-05-2020

Ratios
Key figures 26-05-2020
Cash flow
P/C 0,38
   
P/FC 0,46
Balance sheet
ROI-9,64
ROE18,77
Income statement
P/E-0,28
Div. Yield0,00%
P/B0,15
P/S0,09


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMNK
Market Capitalization282.677.280,00 USD
CountryIreland
IndicesS&P 500
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.mallinckrodt.com


Description of the company

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.mallinckrodt.com